Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Colorectal Neoplasms

Free Subscription 21.08.2018 10 BMC Cancer 1 Br J Cancer 1 Br J Surg 2 Cancer Lett 2 Clin Cancer Res 1 Eur J Cancer 3 Gastroenterology 2 Gut 2 Hum Pathol 2 Int J Cancer 3 Int J Colorectal Dis 1 Int J Oncol 1 J Pathol 1 Lancet Gastroenterol Hepatol 4 Oncol Rep 1 PLoS Med 2 PLoS One 3 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

BMC Cancer

1. RUDERMAN S, Eshein A, Valuckaite V, Dougherty U, et al
   Early increase in blood supply (EIBS) is associated with tumor risk in the Azoxymethane model of colon cancer.
   BMC Cancer. 2018;18:814.
   PubMed     Text format     Abstract available
   
   
2. SABER MM, Al-Mahallawi AM, Nassar NN, Stork B, et al
   Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes.
   BMC Cancer. 2018;18:822.
   PubMed     Text format     Abstract available
   
   
3. DEPCZYNSKI J, Dobbins T, Armstrong B, Lower T, et al
   Comparison of cancer incidence in Australian farm residents 45 years and over, compared to rural non-farm and urban residents - a data linkage study.
   BMC Cancer. 2018;18:33.
   PubMed     Text format     Abstract available
   
   
4. HUEMER F, Thaler J, Piringer G, Hackl H, et al
   Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentose Tumortherapie).
   BMC Cancer. 2018;18:11.
   PubMed     Text format     Abstract available
   
   
5. FENNELL LJ, Jamieson S, McKeone D, Corish T, et al
   MLH1-93 G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAF(V600E) mutation.
   BMC Cancer. 2018;18:35.
   PubMed     Text format     Abstract available
   
   
6. HERNANDEZ RK, Wade SW, Reich A, Pirolli M, et al
   Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
   BMC Cancer. 2018;18:44.
   PubMed     Text format     Abstract available
   
   
7. MARTINEZ-USEROS J, Moreno I, Fernandez-Acenero MJ, Rodriguez-Remirez M, et al
   The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
   BMC Cancer. 2018;18:144.
   PubMed     Text format     Abstract available
   
   
8. ARJONA-SANCHEZ A, Barrios P, Boldo-Roda E, Camps B, et al
   HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma.
   BMC Cancer. 2018;18:183.
   PubMed     Text format     Abstract available
   
   
9. TOSI D, Perez-Gracia E, Atis S, Vie N, et al
   Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
   BMC Cancer. 2018;18:812.
   PubMed     Text format     Abstract available
   
   
10. ARAKAWA K, Hata K, Yamamoto Y, Nishikawa T, et al
    Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum, prostate, and external ear canal-without microsatellite instability: a case report.
    BMC Cancer. 2018;18:24.
    PubMed     Text format     Abstract available
    
    

    
    Br J Cancer

11. MARINGE C, Rachet B, Lyratzopoulos G, Rubio FJ, et al
    Persistent inequalities in unplanned hospitalisation among colon cancer patients across critical phases of their care pathway, England, 2011-13.
    Br J Cancer. 2018 Aug 15. pii: 10.1038/s41416-018-0170.
    PubMed     Text format     Abstract available
    
    

    
    Br J Surg

12. BARE M, Mora L, Tora N, Gil MJ, et al
    CCR-CARESS score for predicting operative mortality in patients with colorectal cancer.
    Br J Surg. 2018 Aug 13. doi: 10.1002/bjs.10956.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

13. LIU Y, Yang EJ, Zhang B, Miao Z, et al
    PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A.
    Cancer Lett. 2018 Aug 14. pii: S0304-3835(18)30523.
    PubMed     Text format     Abstract available
    
    
14. TAN X, Zhang Z, Yao H, Shen L, et al
    Tim-4 promotes the growth of colorectal cancer by activating angiogenesis and recruiting tumor-associated macrophages via the PI3K/AKT/mTOR signaling pathway.
    Cancer Lett. 2018 Aug 14. pii: S0304-3835(18)30524.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

15. LAURENT-PUIG P, Grisoni ML, Heinemann V, Liebaert F, et al
    Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.
    Clin Cancer Res. 2018 Aug 14. pii: 1078-0432.CCR-18-1324.
    PubMed     Text format     Abstract available
    
    
16. LEE V, Wang JS, Zahurak ML, Gootjes EC, et al
    A phase I trial of a guadecitabine (SGI-110) and irinotecan in metastatic colorectal cancer patients previously exposed to irinotecan.
    Clin Cancer Res. 2018 Aug 10. pii: 1078-0432.CCR-18-0421.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cancer

17. MADI A, Fisher D, Maughan TS, Colley JP, et al
    Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
    Eur J Cancer. 2018;102:31-39.
    PubMed     Text format     Abstract available
    
    

    
    Gastroenterology

18. LEDDIN D, Lieberman DA, Tse F, Barkun AN, et al
    Clinical Practice Guideline on Screening for Colorectal Cancer in individuals with a Family History of Nonhereditary Colorectal Cancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus.
    Gastroenterology. 2018 Aug 16. pii: S0016-5085(18)34882.
    PubMed     Text format     Abstract available
    
    
19. SETHI V, Kurtom S, Tarique M, Lavania S, et al
    Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response.
    Gastroenterology. 2018;155:33-37.
    PubMed     Text format     Abstract available
    
    
20. ONER MG, Rokavec M, Kaller M, Bouznad N, et al
    Combined Inactivation of TP53 and MIR34A Promotes Colorectal Cancer Development and Progression in Mice via Increasing Levels of IL6R and PAI1.
    Gastroenterology. 2018 Aug 9. pii: S0016-5085(18)34868.
    PubMed     Text format     Abstract available
    
    

    
    Gut

21. TOYOSHIMA O, Hata K, Yoshida S, Arita M, et al
    New-generation chromoendoscopy may increase confidence in the DISCARD2 study.
    Gut. 2018;67:1742-1743.
    PubMed     Text format    
    
    
22. TOES-ZOUTENDIJK E, Kooyker AI, Elferink MA, Spaander MCW, et al
    Stage distribution of screen-detected colorectal cancers in the Netherlands.
    Gut. 2018;67:1745-1746.
    PubMed     Text format    
    
    

    
    Hum Pathol

23. LIU Y, Peng K, Xie R, Zheng J, et al
    Protocadherin gamma A7 is down-regulated in colorectal cancer and associated with the prognosis in patients with wild-type KRAS.
    Hum Pathol. 2018 Aug 16. pii: S0046-8177(18)30312.
    PubMed     Text format     Abstract available
    
    
24. CUI G, Cai F, Ding Z, Gao L, et al
    MMP14 predicts a poor prognosis in patients with colorectal cancer.
    Hum Pathol. 2018 Aug 15. pii: S0046-8177(18)30310.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

25. EILERTSEN IA, Sveen A, Stromme JM, Skotheim RI, et al
    Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer.
    Int J Cancer. 2018 Aug 19. doi: 10.1002/ijc.31809.
    PubMed     Text format     Abstract available
    
    
26. KOREHISA S, Oki E, Iimori M, Nakaji Y, et al
    Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Int J Cancer. 2018;142:822-832.
    PubMed     Text format     Abstract available
    
    

    
    Int J Colorectal Dis

27. SVERRISSON I, Nikberg M, Chabok A, Smedh K, et al
    Low risk of intra-abdominal infections in rectal cancer patients treated with Hartmann's procedure: a report from a national registry.
    Int J Colorectal Dis. 2018;33:327-332.
    PubMed     Text format     Abstract available
    
    
28. TOLSTRUP R, Funder JA, Lundbech L, Thomassen N, et al
    Perioperative pain after robot-assisted versus laparoscopic rectal resection.
    Int J Colorectal Dis. 2018;33:285-289.
    PubMed     Text format     Abstract available
    
    
29. DULSKAS A, Smolskas E, Kildusiene I, Samalavicius NE, et al
    Treatment possibilities for low anterior resection syndrome: a review of the literature.
    Int J Colorectal Dis. 2018;33:251-260.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

30. WANG Z, Zhao X, Wang W, Liu Y, et al
    ZBTB7 evokes 5-fluorouracil resistance in colorectal cancer through the NFkappaB signaling pathway.
    Int J Oncol. 2018 Aug 10. doi: 10.3892/ijo.2018.4521.
    PubMed     Text format     Abstract available
    
    

    
    J Pathol

31. MCCORRY AMB, Loughrey MB, Longley DB, Lawler M, et al
    Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition.
    J Pathol. 2018 Aug 13. doi: 10.1002/path.5155.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Gastroenterol Hepatol

32. KELLER DS, Ishizawa T, Cohen R, Chand M, et al
    Indocyanine green fluorescence imaging in colorectal surgery: overview, applications, and future directions.
    Lancet Gastroenterol Hepatol. 2017;2:757-766.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

33. QIAO P, Li S, Zhang H, Yao L, et al
    Farnesoid X receptor inhibits proliferation of human colorectal cancer cells via the miR135A1/CCNG2 signaling pathway.
    Oncol Rep. 2018;40:2067-2078.
    PubMed     Text format     Abstract available
    
    
34. WU J, Zhao R, Lin J, Liu B, et al
    Integrin beta4 reduces DNA damageinduced p53 activation in colorectal cancer.
    Oncol Rep. 2018;40:2183-2192.
    PubMed     Text format     Abstract available
    
    
35. LIU BS, Xia HW, Zhou S, Liu Q, et al
    Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
    Oncol Rep. 2018;40:2171-2182.
    PubMed     Text format     Abstract available
    
    
36. ZHOU N, Sun Z, Li N, Ge Y, et al
    miR197 promotes the invasion and migration of colorectal cancer by targeting insulinlike growth factorbinding protein 3.
    Oncol Rep. 2018 Aug 10. doi: 10.3892/or.2018.6640.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Med

37. DILLON M, Flander L, Buchanan DD, Macrae FA, et al
    Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    PLoS Med. 2018;15:e1002630.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

38. PAL R, Wei N, Song N, Wu S, et al
    Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations.
    PLoS One. 2018;13:e0200836.
    PubMed     Text format     Abstract available
    
    
39. DEN BAKKER CM, Anema JR, Zaman AGNM, de Vet HCW, et al
    Prognostic factors for return to work and work disability among colorectal cancer survivors; A systematic review.
    PLoS One. 2018;13:e0200720.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

40. SUAREZ-LOPEZ L, Sriram G, Kong YW, Morandell S, et al
    MK2 contributes to tumor progression by promoting M2 macrophage polarization and tumor angiogenesis.
    Proc Natl Acad Sci U S A. 2018;115:E4236-E4244.
    PubMed     Text format     Abstract available
    
    
41. DORSAM B, Seiwert N, Foersch S, Stroh S, et al
    PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression.
    Proc Natl Acad Sci U S A. 2018;115:E4061-E4070.
    PubMed     Text format     Abstract available
    
    
42. NTAI I, Fornelli L, DeHart CJ, Hutton JE, et al
    Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk.
    Proc Natl Acad Sci U S A. 2018;115:4140-4145.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: